Importantly, daratumumab‐dependent phagocytosis was demonstrated ex vivo in 11 of 12 patient‐derived MM cell isolates with variable levels of CD38 expression 81, suggesting that phagocytosis is a clinically relevant mechanism of action that may contribute to the therapeutic activity of daratumumab. Here, CD38 is linked to Miyoshi myopathy.